GlassScriptPhysician profile
Haris Riaz
NPI 1689081069
$2,454.56
in general payments reported to CMS, 2019-2025
10 companies · $1,600 in 2025
The $1,600 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $299 · 2022: $26.21 · 2023: $375 · 2024: $155 · 2025: $1,600.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,220 · Food and Beverage: $877 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,219.94 |
| Food and Beverage | $877.40 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,759.54 | 2021-2025 | Esprit, Supera, Diamondback Peripheral |
| Shockwave Medical, INC | $382.47 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Abiomed | $80.33 | 2023-2025 | Impella |
| Novo Nordisk INC | $49.18 | 2025 | Wegovy |
| Merck Sharp & Dohme LLC | $48.49 | 2021 | |
| Cardiovascular Systems INC. | $46.07 | 2022-2023 | Diamondback Coronary |
| Amgen INC. | $28.98 | 2021-2024 | Repatha |
| Janssen Pharmaceuticals, INC | $22.53 | 2021 | |
| Novartis Pharmaceuticals Corporation | $18.73 | 2023 | |
| Cardiva Medical, INC. | $18.24 | 2024 | Cardiva Vascade 6/7f Vcs |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haris Riaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.